Moreover, the treatment with the activin A binding protein follistatin or RAP-011 (a ligand trap of ActRIIA) has revealed amelioration of renal fibrosis and CKD-MBD findings in CKD models [136,137,138]. This evidence concerns the gene ACVR2A and chronic kidney disease.